Avonex is a prescription drug that treats relapsing forms of multiple sclerosis (MS) in adults, such as relapsing-remitting MS, active secondary progressive MS, and clinically isolated syndrome.

Avonex is typically prescribed as a long-term treatment for relapsing forms of multiple sclerosis (MS). The standard dosage is 30 micrograms (mcg) injected into the upper outer thigh muscle once per ...

The late Lawrence Jacobs, MD, a UB professor of neurology, was determined to improve the lives of his patients. His resolve led to groundbreaking research on multiple sclerosis (MS)—most notably the ...

Patients taking the multiple sclerosis (MS) drug Avonex (search) should be watched for possible liver problems, says the drug’s maker. Rare cases of severe liver injury, including cases of liver ...

March 17, 2005 — The U.S. Food and Drug Administration (FDA) and Biogen Idec have warned healthcare professionals via letter of rare postmarketing reports of severe hepatic injury in patients ...

Biogen Idec has won European regulatory approval for a new delivery method for its blockbuster multiple sclerosis (MS) drug, Avonex, called the Avonex Pen. This is the first approval for the Avonex ...

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Biogen Idec Canada Inc today announced AVONEX ® PEN ™ is now available for patients with relapsing multiple sclerosis (MS) and patients with a single ...

Anniversary Celebration Includes NASDAQ Ceremonial Bell Ringing, Educational Events, Commemorative Book and Video Biogen Idec (NASDAQ:BIIB) today marks the 10th anniversary of AVONEX(R) (Interferon ...

Biogen's newly approved, once-monthly MS drug Zinbryta comes with more serious side effects than predecessor Avonex. But the med is safer than a competing treatment ...

Avonex, a groundbreaking once-weekly treatment for relapsing multiple sclerosis when it first gained FDA approval in 1996, generated $2.7 billion of the company's $5 billion in revenue during 2011.